List of Vasostrict drug patents
Vasostrict is owned by Par Sterile Products.
Vasostrict contains Vasopressin.
Vasostrict has a total of 14 drug patents out of which 0 drug patents have expired.
Vasostrict was authorised for market use on 17 April, 2014.
Vasostrict is available in solution;intravenous dosage forms.
Vasostrict can be used as to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.
The generics of Vasostrict are possible to be released after 30 January, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9375478 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9744209 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9937223 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9744239 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US10010575 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9981006 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9974827 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9968649 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9962422 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9925234 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9925233 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9687526 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9750785 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9919026 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
Drugs and Companies using VASOPRESSIN ingredient
Market Authorisation Date: 17 April, 2014
Treatment: To increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines
Dosage: SOLUTION;INTRAVENOUS
VASOSTRICT family patents
38
United States
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic